Arena Pharmaceuticals Inc, San Diego, has announced positive results for the Phase 2 clinical trials of APD125, a drug designed for patients with chronic insomnia.

When compared to placebo, patients treated with APD125 experienced statistically significant improvements in measurements of sleep maintenance, or the persistence of the sleep state after initial onset. No negative next-day side effects were observed.

In addition, REM sleep was not significantly affected. In accordance with the researchers’ expectations, no improvement in sleep onset was recorded.

To read full release, click here.